Skip to main
HSCS

HSCS Stock Forecast & Price Target

HSCS Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

HeartSciences Inc is experiencing a positive shift in its financial projections, with its FY26 EPS estimates being raised significantly from $(8.63) to $(4.17) due to an increase in share count, indicating improved expectations for the company's performance. The anticipated FDA approval of the MyoVista device and its accompanying algorithm is expected to significantly enhance the market presence of both the MyoVista device and the MyoVista Insights cloud software platform, positioning the company for substantial growth. With a new price target of $9.20 reflecting a threefold potential increase, HeartSciences is poised to capitalize on a large market opportunity in the cardiac diagnostic sector.

Bears say

HeartSciences Inc. faces a significant downward revision of its FY2026 revenue estimate, decreasing from $1.2 million to $0.1 million due to FDA-related delays, which underscores substantial challenges in bringing products to market. The company’s operating expenses remain relatively controlled, coming in at $1.9 million against estimates of $2.0 million; however, this is overshadowed by the myriad risks it faces, including balance sheet and liquidity risks, along with potential failure in clinical trials and regulatory approvals. Overall, the combination of these revenue forecasts and associated risks raises serious concerns about HeartSciences's ability to effectively commercialize its AI-powered ECG diagnostic solutions in a competitive healthcare landscape.

HSCS has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Heart Test Laboratories Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Heart Test Laboratories Inc (HSCS) Forecast

Analysts have given HSCS a Strong Buy based on their latest research and market trends.

According to 1 analysts, HSCS has a Strong Buy consensus rating as of Feb 7, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $9.20, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $9.20, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Heart Test Laboratories Inc (HSCS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.